Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers.

Approximately 4% of people aged 40 years and older have corneal endothelial disease/dystrophy (CED) affecting the back of the cornea, and corneal transplantation is the only treatment option for ...

we would think that there's a condition in their eye that would be causing that— something again that would be maybe a corneal dystrophy, or obviously if they wear contact lenses then there ...

Design Therapeutics, Inc., a biotechnology company focused on treatments for genetic diseases, announced it will provide an update on its DT-168 program for Fuchs endothelial corneal dystrophy ...

Laser refractive surgery has transformed the lives of millions by eliminating the need for glasses or contact lenses. This ...

In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product ...